CD5 and non-small cell lung carcinoma: In a retrospective analysis of non-small cell lung cancer (NSCLC) patients undergoing anti-PD-1/PD-L1 therapy, those with higher CD5 expression on their effector memory T cells (Tem) showed improved responses compared to those with lower expression (Kim et al. 2023).